Amedisys (NAS: AMED) reported earnings on Feb. 28. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Amedisys met expectations on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share shrank significantly.
Margins dropped across the board.
Amedisys reported revenue of $370.7 million. The 12 analysts polled by S&P Capital IQ wanted to see revenue of $371.3 million on the same basis. GAAP reported sales were 6.0% lower than the prior-year quarter's $394.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.49. The 13 earnings estimates compiled by S&P Capital IQ anticipated $0.31 per share on the same basis. GAAP EPS of $0.15 for Q4 were 81% lower than the prior-year quarter's $0.77 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 45.5%, 360 basis points worse than the prior-year quarter. Operating margin was 5.5%, 560 basis points worse than the prior-year quarter. Net margin was 1.2%, 440 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $357.9 million. On the bottom line, the average EPS estimate is $0.19.
Next year's average estimate for revenue is $1.46 billion. The average EPS estimate is $0.98.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 846 members out of 939 rating the stock outperform, and 93 members rating it underperform. Among 251 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 216 give Amedisys a green thumbs-up, and 35 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $10.85.
Over the decades, small-cap stocks, like Amedisys have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
Add Amedisys to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.